Abstract

The Vector Core is a critical resource to members of the Institute for Human Gene Therapy providing access to a wide array of gene transfer technology. This dedicated facility is run by Dr. Guang-ping Gao, who has extensive academic based experience in recombinant viruses. The Core has assembled a comprehensive inventory of plasmids, cell lines, and viruses useful to the development of vectors. More comprehensive service is provided in the design, creation, production, and analysis of recombinant viruses. A number of vector systems are available through the Core, including murine-based retroviruses, adenoviruses, and adeno-associated viruses (AAV). The Vector Core maintains strong links to key laboratories in the Institute for Human Gone Therapy involved in novel vector development. Relevant innovations are quickly brought into the Vector Core, where they are validated and distributed to faculty. In the context of this P01, the Vector Core will play an important role. Methodology for creating chimpanzee adenoviruses will be developed in Project 1 and transferred to the Core who will provide services in terms of vector creation and expansion for all four projects.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
1P01AI052271-01
Application #
6569550
Study Section
Special Emphasis Panel (ZRG1)
Project Start
2002-04-01
Project End
2007-03-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2002
Total Cost
Indirect Cost

  Institution

Name
Wistar Institute
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104

  Publications

Emmer, Kristel L; Wieczorek, Lindsay; Tuyishime, Steven et al. (2016) Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140. AIDS 30:2405-2414
Lasaro, Marcio O; Sazanovich, Marina; Giles-Davis, Wynetta et al. (2011) Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. Mol Ther 19:1727-36
Small, Juliana C; Ertl, Hildegund C J (2011) Viruses - from pathogens to vaccine carriers. Curr Opin Virol 1:241-5
Zhou, Dongming; Zhou, Xiangyang; Bian, Ang et al. (2010) An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc 5:1775-1785
Lasaro, Marcio O; Ertl, Hildegund C J (2010) Targeting inhibitory pathways in cancer immunotherapy. Curr Opin Immunol 22:385-90
Pichla-Gollon, Susan L; Lin, Shih-Wen; Hensley, Scott E et al. (2009) Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. J Virol 83:5567-73
Tatsis, Nia; Lasaro, Marcio O; Lin, Shih-Wen et al. (2009) Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens. J Immunol 182:6587-99
Santra, Sampa; Sun, Yue; Korioth-Schmitz, Birgit et al. (2009) Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 27:5837-45
Haut, Larissa Herkenhoff; Ertl, Hildegund C J (2009) Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. J Leukoc Biol 86:779-93
Lasaro, Marcio O; Tatsis, Nia; Hensley, Scott E et al. (2008) Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat Med 14:205-12

Showing the most recent 10 out of 22 publications